{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:05:10Z","timestamp":1789733110826,"version":"4.0.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00415-025-13135-8","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T11:47:37Z","timestamp":1747223257000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Fenfluramine: an effective treatment for developmental epileptic encephalopathies beyond Dravet and Lennox\u2013Gastaut Syndromes"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8358-2901","authenticated-orcid":false,"given":"Victor","family":"Soto-Insuga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Conejo Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gonz\u00e1lez-Alguacil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Aledo Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Navarro Abia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Gretel Pinz\u00f3n-Acevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Lamagrande Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Duat Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Cantar\u00edn Extremera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Garc\u00eda Pe\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"issue":"6","key":"13135_CR1","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/epi.17239","volume":"63","author":"SM Zuberi","year":"2022","unstructured":"Zuberi SM, Wirrell E, Yozawitz E, Wilmshurst JM, Specchio N, Riney K et al (2022) ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 63(6):1349\u20131397","journal-title":"Epilepsia"},{"issue":"1","key":"13135_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S1474-4422(08)70292-8","volume":"8","author":"A Arzimanoglou","year":"2009","unstructured":"Arzimanoglou A, French J, Blume WT, Cross JH, Ernst JP, Feucht M et al (2009) Lennox\u2013Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol 8(1):82\u201393","journal-title":"Lancet Neurol"},{"issue":"3","key":"13135_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40272-016-0171-7","volume":"18","author":"A Wallace","year":"2016","unstructured":"Wallace A, Wirrell E, Kenney-Jung DL (2016) Pharmacotherapy for Dravet syndrome. Pediatr Drugs 18(3):197\u2013208","journal-title":"Pediatr Drugs"},{"issue":"2","key":"13135_CR4","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.resp.2013.06.026","volume":"189","author":"F Kalume","year":"2013","unstructured":"Kalume F (2013) Sudden unexpected death in Dravet syndrome: Respiratory and other physiological dysfunctions. Respir Physiol Neurobiol 189(2):324\u2013328","journal-title":"Respir Physiol Neurobiol"},{"issue":"5","key":"13135_CR5","first-page":"255","volume":"44","author":"D Lazaridis","year":"2019","unstructured":"Lazaridis D, Eraikhuemen N, Williams K, Lovince J (2019) Treatment of seizures associated with Lennox\u2013Gastaut and Dravet syndromes: a focus on cannabidiol oral solution. Pharm Ther 44(5):255\u2013266","journal-title":"Pharm Ther"},{"key":"13135_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.yebeh.2017.02.003","volume":"70","author":"MP Jensen","year":"2017","unstructured":"Jensen MP, Brunklaus A, Dorris L, Zuberi SM, Knupp KG, Galer BS et al (2017) The humanistic and economic burden of Dravet syndrome on caregivers and families: Implications for future research. Epilepsy Behav 70:104\u2013109","journal-title":"Epilepsy Behav"},{"key":"13135_CR7","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2147\/JMDH.S69300","volume":"7","author":"PA Gibson","year":"2014","unstructured":"Gibson PA (2014) Lennox\u2013Gastaut syndrome: impact on the caregivers and families of patients. J Multidiscip Healthc 7:441\u2013448","journal-title":"J Multidiscip Healthc"},{"key":"13135_CR8","unstructured":"FINTEPLA Summary of Product Characteristics. [Internet]. [cited 2024]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fintepla-epar-product-information_en.pdf"},{"issue":"3","key":"13135_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40263-022-00898-1","volume":"36","author":"A Strzelczyk","year":"2022","unstructured":"Strzelczyk A, Schubert-Bast S (2022) A practical guide to the treatment of Dravet syndrome with anti-seizure medication. CNS Drugs 36(3):217\u2013237","journal-title":"CNS Drugs"},{"issue":"1","key":"13135_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40263-020-00784-8","volume":"35","author":"A Strzelczyk","year":"2021","unstructured":"Strzelczyk A, Schubert-Bast S (2021) Expanding the treatment landscape for Lennox\u2013Gastaut syndrome: current and future strategies. CNS Drugs 35(1):61\u201383","journal-title":"CNS Drugs"},{"issue":"8","key":"13135_CR11","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.3390\/children9081159","volume":"9","author":"D Samanta","year":"2022","unstructured":"Samanta D (2022) Fenfluramine: a review of pharmacology, clinical efficacy, and safety in epilepsy. Children 9(8):1159","journal-title":"Children"},{"issue":"16","key":"13135_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/ijms22168416","volume":"22","author":"P Martin","year":"2021","unstructured":"Martin P, Reeder T, Sourbron J, de Witte PAM, Gammaitoni AR, Galer BS (2021) An emerging role for sigma-1 receptors in the treatment of developmental and epileptic encephalopathies. Int J Mol Sci 22(16):22\u201328","journal-title":"Int J Mol Sci"},{"issue":"10216","key":"13135_CR13","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","volume":"394","author":"L Lagae","year":"2019","unstructured":"Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M et al (2019) Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 394(10216):2243\u20132254","journal-title":"Lancet"},{"issue":"3","key":"13135_CR14","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1001\/jamaneurol.2019.4113","volume":"77","author":"R Nabbout","year":"2020","unstructured":"Nabbout R, Mistry A, Zuberi S, Villeneuve N, Gil-Nagel A, Sanchez-Carpintero R et al (2020) Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol 77(3):300\u2013308","journal-title":"JAMA Neurol"},{"issue":"6","key":"13135_CR15","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/jamaneurol.2022.0829","volume":"79","author":"KG Knupp","year":"2022","unstructured":"Knupp KG, Scheffer IE, Ceulemans B, Sullivan JE, Nickels KC, Lagae L et al (2022) Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox\u2013Gastaut syndrome: a randomized clinical trial. JAMA Neurol 79(6):554\u2013564","journal-title":"JAMA Neurol"},{"issue":"1","key":"13135_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/epi.17431","volume":"64","author":"KG Knupp","year":"2023","unstructured":"Knupp KG, Scheffer IE, Ceulemans B, Sullivan J, Nickels KC, Lagae L et al (2023) Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox\u2013Gastaut syndrome: interim analysis of an open-label extension study. Epilepsia 64(1):139\u2013151","journal-title":"Epilepsia"},{"key":"13135_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108994","volume":"138","author":"KI Bishop","year":"2023","unstructured":"Bishop KI, Isquith PK, Gioia GA, Knupp KG, Scheffer IE, Nabbout R et al (2023) Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (<5 years) with Dravet syndrome. Epilepsy Behav 138:108994","journal-title":"Epilepsy Behav"},{"key":"13135_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.seizure.2021.10.024","volume":"93","author":"JH Cross","year":"2021","unstructured":"Cross JH, Galer BS, Gil-Nagel A, Devinsky O, Ceulemans B, Lagae L et al (2021) Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome. Seizure 93:154\u2013159","journal-title":"Seizure"},{"issue":"3","key":"13135_CR19","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/epi4.12623","volume":"7","author":"\u00c1 Aledo-Serrano","year":"2022","unstructured":"Aledo-Serrano \u00c1, Cabal-Paz B, Gardella E, G\u00f3mez-Porro P, Mart\u00ednez-M\u00fagica O, Beltr\u00e1n-Corbellini A et al (2022) Effect of fenfluramine on seizures and comorbidities in SCN8A-developmental and epileptic encephalopathy: a case series. Epilepsia Open 7(3):525\u2013531","journal-title":"Epilepsia Open"},{"issue":"12","key":"13135_CR20","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1111\/dmcn.14965","volume":"63","author":"KR Geenen","year":"2021","unstructured":"Geenen KR, Doshi SP, Patel S, Sourbron J, Falk A, Morgan A et al (2021) Fenfluramine for seizures associated with sunflower syndrome. Dev Med Child Neurol 63(12):1427\u20131432","journal-title":"Dev Med Child Neurol"},{"issue":"7","key":"13135_CR21","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1111\/epi.16923","volume":"62","author":"O Devinsky","year":"2021","unstructured":"Devinsky O, King LT, Schwartz D, Conway E, Price D (2021) Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder. Epilepsia 62(7):e98-102","journal-title":"Epilepsia"},{"issue":"6","key":"13135_CR22","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/epi.17241","volume":"63","author":"N Specchio","year":"2022","unstructured":"Specchio N, Wirrell EC, Scheffer IE, Nabbout R, Riney K, Samia P et al (2022) International league against epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE task force on nosology and definitions. Epilepsia 63(6):1398\u20131442","journal-title":"Epilepsia"},{"issue":"10","key":"13135_CR23","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S1474-4422(16)30158-2","volume":"15","author":"O Devinsky","year":"2016","unstructured":"Devinsky O, Hesdorffer DC, Thurman DJ, Lhatoo S, Richerson G (2016) Sudden unexpected death in epilepsy: epidemiology, mechanisms, and prevention. Lancet Neurol 15(10):1075\u20131088","journal-title":"Lancet Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13135-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13135-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13135-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T13:25:26Z","timestamp":1749907526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13135-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["13135"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13135-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"VSI, EGA, ADR and JJDP received fees for Advisory Boards, travel, and registration for Scientific Meetings from UCB, Eisai, Nutricia, Biocodex, GW-Jazz Pharmaceuticals, and Takeda. DCM and VCE received fees for Advisory Boards, travel, and registration for Scientific Meetings from UCB, Eisai, Nutricia and GW-Jazz Pharmaceuticals. NLC has received fees for Scientific Meetings from UCB, GW-Jazz Pharmaceuticals and Biocodex.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"397"}}